new weight loss drug semaglutide Novo Nordisk's weight-loss pill wins FDA approval Wegovy pill debuts at $149

Regulatory Timeline Context Health Canada continues reviewing the nine pending generic applications following the January 4, 2026 patent expiration

Lifestyle Gaps That Prevent Weight Loss on GLP-1 Therapy Semaglutide suppresses appetite but does not eliminate the need for intentional nutrition choices

However, by 30 days past the printed date, the same vial could contain as little as 7085% of the original concentration

Patients who experience rapid dose escalation may be more prone to fatigue and gastrointestinal symptoms

Pancreatic enzymes (amylase and lipase) should remain normal on semaglutide unless you have a history of pancreatitis